Management of Palpitations with Beta-Blockers

Introduction to Beta-Blocker Therapy

Beta-blockers are the most appropriate medication for treating palpitations without causing hypotension, particularly metoprolol, atenolol, or propranolol, as recommended by the American College of Cardiology and the European Society of Cardiology 1, 2

Beta-blockers effectively control heart rate and reduce palpitations by antagonizing the effects of increased sympathetic tone, making them ideal first-line agents for symptomatic palpitations, with a strength of evidence level of A, according to the American Heart Association 3, 2
Beta-blockers are particularly effective for palpitations associated with mild tachyarrhythmias or increased adrenergic symptoms, with a high level of evidence supporting their use, as stated by the European Society of Cardiology 3

Unlike calcium channel blockers, beta-blockers can be titrated to control heart rate with minimal impact on blood pressure in normotensive patients, as noted by the American College of Cardiology 4, 5
For patients with palpitations who also have hypertension, beta-blockers provide dual benefit of treating both conditions simultaneously, with a strong recommendation from the American Heart Association 1, 6

Beta-blockers are especially effective for patients with palpitations associated with anxiety or increased adrenergic tone, with a high level of evidence supporting their use, as stated by the American College of Cardiology and the European Society of Cardiology 3, 1
Beta-blockers are also effective for patients with supraventricular arrhythmias causing symptomatic palpitations, with a strong recommendation from the European Society of Cardiology and the American College of Cardiology 2, 4

The American College of Cardiology recommends starting with low doses of beta-blockers, such as metoprolol (25mg twice daily) or atenolol (25mg daily), and titrating gradually to minimize side effects, with a strength of evidence level of B 5, 2

The American Heart Association recommends that patients with recurrent palpitations undergo continuous or event-activated ambulatory ECG recordings to identify the underlying rhythm disturbance, with a high level of evidence supporting this approach 3
The European Society of Cardiology suggests evaluating for structural heart disease with echocardiography before starting antiarrhythmic therapy, with a strong recommendation 7

The American College of Cardiology and the European Society of Cardiology recommend a treatment algorithm for palpitations, starting with beta-blockers (metoprolol, atenolol, or propranolol) as first-line therapy, with a high level of evidence supporting this approach 1, 2
For second-line treatment, the European Society of Cardiology suggests flecainide or propafenone for patients with no structural heart disease, with a moderate level of evidence supporting this approach 7, 2
For third-line treatment, the European Society of Cardiology recommends amiodarone for refractory cases, with a low level of evidence supporting this approach 7, 2